Short Bowel Syndrome and Teduglutide

Introduction To Pediatric Short Bowel Syndrome

Short Bowel Syndrome (SBS) represents the leading cause of pediatric Intestinal Failure (IF).
It primarily results from massive surgical resection secondary to Necrotizing Enterocolitis, midgut volvulus, complicated gastroschisis, or intestinal atresias.
Massive mucosal surface area loss creates dependence on Parenteral Nutrition (PN), risking lethal complications like catheter-related bloodstream infections, venous thrombosis, and Intestinal Failure-Associated Liver Disease (IFALD).
The ultimate therapeutic goal is achieving complete enteral autonomy via physiological intestinal adaptation.

Endogenous Glucagon-Like Peptide-2 (GLP-2) is secreted by distal ileum L-cells to drive intestinal adaptation, but SBS patients suffer from chronic GLP-2 deficiency following resection.

Pharmacological Parameter	Mechanism And Clinical Action
Drug Engineering	Teduglutide is a recombinant GLP-2 analog featuring a glycine substitution at position 2, rendering it highly resistant to Dipeptidyl Peptidase-4 (DPP-4) degradation and extending its half-life.
Physiological Effects	Stimulates crypt stem cell proliferation, dramatically increases villus height and mucosal surface area, enhances splanchnic blood flow, upregulates tight junction proteins to improve barrier function, and slows gastric emptying.
Clinical Dosing	Approved for pediatric SBS-IF patients aged 1 year and older, administered at 0.05 mg/kg/day via subcutaneous injection.

Long-term 96-week data confirms progressive reductions in daily PN volume and caloric requirements, enabling 15 to 35% of pediatric cohorts to achieve total enteral autonomy.
Pediatric patients also demonstrate significant improvements in stool consistency and frequency.
Highly safe and effective in extremely low-weight infants (under 10 kg), demonstrating a 46.6% reduction in parenteral calories without compromising linear growth.
Pre-treatment predictors of excellent clinical response include longer residual small bowel length, normal liver enzymes, and high baseline plasma Citrulline levels.

Requires a highly structured, multidisciplinary PN weaning protocol to safely challenge the gut while preventing severe dehydration or hypervolemia.

Adverse Event Risk	Mandated Surveillance Protocol
Neoplastic Polyps	Baseline fecal occult blood and full colonoscopy, repeated at 1 year post-initiation, and subsequently every 3 to 5 years.
Fluid Overload	Vigilant monitoring for congestive heart failure triggered by the massive, rapid improvement in fluid absorption capacity.
Hepatobiliary Disease	Routine hepatobiliary ultrasound combined with serial amylase, lipase, and bilirubin checks every 6 months to monitor for cholelithiasis and pancreatitis.
Intestinal Obstruction	Clinical monitoring for mechanical obstruction secondary to rapid bowel wall thickening at prior surgical anastomoses.

Exorbitant drug costs completely restrict access for the vast majority of Indian patients, maintaining heavy reliance on surgical interventions like the Serial Transverse Enteroplasty (STEP) procedure.
Emerging 2026 pipeline therapies include next-generation, long-acting GLP-2 analogues (Apraglutide, Glepaglutide) designed for convenient once-weekly subcutaneous injections.
Impending patent expirations are anticipated to introduce affordable generic biosimilars, vastly improving access in Low- and Middle-Income Countries.